Drugs / Farletuzumab Ecteribulin
Farletuzumab Ecteribulin
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03386942 | Nov 2017 → Oct 2022 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04300556 | Aug 2020 → Aug 2030 expected | cancer | Eisai Inc. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05613088 | Feb 2023 → Jun 2024 | ovarian neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT05577715 | Nov 2022 → Aug 2024 | non-small cell lung carcinoma | Bristol-Myers Squibb | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Farletuzumab ecteribulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04300556 ↗ |
| Known as | Farletuzumab ecteribul | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802212 ↗ |
| Known as | FZEC | “Farletuzumab ecteribulin (FZEC), an antibody-drug conjugate targeting folate receptor-alpha (FRα)” PMID 41993769 ↗ Jan 2026 |
| Known as | MORAb-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05613088 ↗ |
| Route | Intravenous | “farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks” NCT03386942 ↗ |